A new life-saving intervention under development could be taken easily wherever it’s most needed, like the battlefield, in ...

Agios Pharmaceuticals plans to share data from RISE UP with the Food and Drug Administration to support the approval of the sickle cell disease indication.

Agios Pharmaceuticals stock shed about half its value Wednesday after the company's sickle cell disease treatment lagged ...

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

What Are Biomarkers? A Guide to Understanding the Health Indicators Key Takeaways: Biomarkers — aka biological markers — are ...

Agios Pharmaceuticals, Inc. drops after mixed Phase 3 mitapivat results in Sickle Cell Disease. Click here to find out why ...

Please provide your email address to receive an email when new articles are posted on . Men with anemia were more likely to have correction of their condition with testosterone therapy vs. placebo.

Novartis AG NVS released detailed results from the Phase 3 APPOINT-PNH trial of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults with ...

This retrospective longitudinal cohort study used a database of outpatient oncology practice electronic medical records from January 1, 2006, to August 6, 2009. Unit of analysis was episode of ...

NOTE. Year 2006 used as comparator for descriptive, between-year comparisons. Abbreviation: ESA, erythropoietin-stimulating agent. Year-to-year comparisons for all tumor types were statistically ...